Sable is redefining fat reduction through biotechnology. Stubborn pockets of subcutaneous fat—under the chin, on the thighs, and around the arms—often persist despite diet and exercise. Yet today’s topical “slimming” products rely largely on cosmetic actives like caffeine, with little scientific evidence supporting meaningful results.

Born from groundbreaking research at Columbia University Medical Center, Sable’s lead compound, SBL-001, has been shown to selectively target fat cells and reduce their volume by up to 70%. Leveraging advanced formulation science, the company is developing this patented nanomaterial into a line of effective, biotechnology-driven topical slimming creams.

Led by Dr. Daniel Chai, Sable plans a multi-channel launch, including dermatology practices, e-commerce, and luxury retail—bringing clinically grounded fat-reduction technology directly to consumers.